On December 23, 2021, Arasappan, Ashok; Bell, Ian M.; Bungard, Christopher James; Burgey, Christopher S.; Cox, Jason M.; Kelly, Michael J., III; Layton, Mark E.; Liu, Hong; Liu, Jian; Perkins, James J.; Shah, Akshay A.; Vanheyst, Michael David; Wu, Zhe published a patent.Safety of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine The title of the patent was 2-Oxoimidazolidine-4-carboxamides as NaV1.8 inhibitors and their preparation. And the patent contained the following:
Compounds of formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. Compounds of formula I wherein one of A and B is (un)substituted aryl and (un)substituted heteroaryl, and the other one of A and B is (un)substituted aryl, (un)substituted heteroaryl, (un)substituted C1-6 alkyl-aryl, (un)substituted C3-8 cycloalkyl-aryl, etc.; R1, R2, R3 and R4 are independently H, (un)substituted C1-6 alkyl, (un)substituted C3-6 alkenyl, (un)substituted C3-6 alkynyl, (un)substituted C3-10 cycloalkyl, etc.; R5 is H and (un)substituted C1-6 alkyl; R6 is H, (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl and (un)substituted C2-6 cycloheteroalkyl; R7 is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl and (un)substituted C2-6 alkynyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their NaV1.8 inhibitory activity (data given). The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).Safety of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine
The Article related to oxoimidazolidinecarboxamide preparation sodium channel inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Safety of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia